Page 943 - Adams and Stashak's Lameness in Horses, 7th Edition

Principles of Therapy for Lameness 909

70. Judson DG, Barton M. Effect of aspirin on haemostasis in the 94. Maitho TE, Lees P, Taylor JB. Absorption and pharmacokinetics
horse. Res Vet Sci 1981;30:241–242. of phenylbutazone in Welsh Mountain ponies. J Vet Pharmacol
Ther 1986;9:26–39.
VetBooks.ir 72. Kawcak CE, Frisbie DD, McIlwraith CW, et al. Evaluation of avo- 95. Maranon G, Munoz‐Escassi B, Manley W, et al. The effect of
71. Karzel K, Lee KJ. Effect of hexosamine derivatives on mesenchy-
mal metabolic processes of in vitro cultured fetal bone explants.
Z Rheumatol 1982;41:212–218.
methyl sulphonyl methane supplementation on biomarkers of
oxidative stress in sport horses following jumping exercise. Acta
Vet Scand 2008;50:45.
cado and soybean unsaponifiable extracts for treatment of horses
with experimentally induced osteoarthritis. Am J Vet Res 2007;68: 96. May SA, Lees P. Nonsteroidal anti‐inflammatory drugs. In Joint
598–604. Disease in the Horse, 1st ed. McIlwraith CW, Trotter GW, eds.
73. Keegan K, Hughes F, Lane T, et al. Effects of an oral nutraceutical WB Saunders, Philadelphia, 1996;223–236.
on clinical aspects of joint disease in a blinded, controlled clinical 97. McIlwraith CW. Medications for joint disease: nonsteroidal
trial: 39 horses. Proc Am Assoc Equine Pract 2007;53:252–255. anti‐inflammatory drugs. In Adams’ Lameness in Horses, 5th ed.
74. Keegan KG, Messer NT, Reed SK, et al. Effectiveness of adminis- Stashak TS, ed. Lippincott Williams and Wilkins, Philadelphia,
tration of phenylbutazone alone or concurrent administration of 2002;494–498.
phenylbutazone and flunixin meglumine to alleviate lameness in 98. McIlwraith CW. Licensed medications, “generic” medications,
horses. Am J Vet Res 2008;69:167–173. compounding, and nutraceuticals—what has been scientifically
75. Keller H, Hashem A. The concentration changes of different phe- validated, where do we encounter scientific mistruth, and
nylbutazone formulations in horse plasma. Dtsch Tierarztl where are we legally? Proc Am Assoc Equine Pract 2004;
Wochenschr 1996;103:224–230. 50:459–475.
76. Kelly GS. The role of glucosamine sulfate and chondroitin sulfates 99. McKellar QA, Bogan JA, von Fellenberg RL, et al. Pharmacokinetic,
in the treatment of degenerative joint disease. Altern Med Rev biochemical and tolerance studies on carprofen in the horse.
1998;3:27–39. Equine Vet J 1991;23:280–284.
77. Kim LS, Axelrod LJ, Howard P, et al. Efficacy of methylsulfonyl- 100. Meade EA, Smith WL, DeWitt DL. Differential inhibition of
methane (MSM) in osteoarthritis pain of the knee: a pilot clinical prostaglandin endoperoxide synthase (cyclooxygenase) isozymes
trial. Osteoarthritis Cartilage 2006;14:286–294. by aspirin and other non‐steroidal anti‐inflammatory drugs.
78. Kirker‐Head CA, Kirker‐Head RP. Safety of an oral chondropro- J Biol Chem 1993;268:6610–6614.
tective agent in horses. Vet Ther 2001;2:345–353. 101. Merial. Horse Owner Survey Shows NSAID Use Trends. April
79. Kivett L, Taintor J, Wright J. Evaluation of the safety of a combi- 30, 2009. www.thehorse.com.
nation of oral administration of phenylbutazone and firocoxib in 102. Meulyzer M, Vachon P, Beaudry F, et al. Comparison of pharma-
horses. J Vet Pharmacol Ther 2013;37:413–416. cokinetics of glucosamine and synovial fluid levels following
80. Knych HK, Stanley SD, Arthur RM, et al. Detection and pharma- administration of glucosamine sulphate or glucosamine hydro-
cokinetics of three formulations of firocoxib following multiple chloride. Osteoarthritis Cartilage 2008;16:973–979.
administrations to horses. Equine Vet J 2014;46:734–738. 103. Meulyzer M, Vachon P, Beaudry F, et al. Joint inflammation
81. Kvaternick V, Pollmeier M, Fischer J, et al. Pharmacokinetics and increases glucosamine levels attained in synovial fluid following
metabolism of orally administered firocoxib, a novel second gen- oral administration of glucosamine hydrochloride. Osteoarthritis
eration coxib, in horses. J Vet Pharmacol Ther 2007;30: Cartilage 2009;17:228–234.
208–217. 104. Morreale P, Manopulo R, Galati M, et al. Comparison of the
82. Laverty S, Sandy JD, Celeste C, et al. Synovial fluid levels and anti‐inflammatory efficacy of chondroitin sulfate and diclofenac
serum pharmacokinetics in a large animal model following treat- sodium in patients with knee osteoarthritis. J Rheumatol
ment with oral glucosamine at clinically relevant doses. Arthritis 1996;23:1385–1391.
Rheum 2005;52:181–191. 105. Moses VS, Hardy J, Bertone AL, et al. Effects of anti‐inflamma-
83. Leatherwood JL, Gehl KL, Coverdale JA, et al. Influence of tory drugs on lipopolysaccharide‐challenged and ‐unchallenged
oral glucosamine supplementation in young horses challenged equine synovial explants. Am J Vet Res 2001;62:54–60.
with intra‐articular lipopolysaccharide. J Anim Sci 2016;94: 106. Moskowitz RW. Role of collagen hydrolysate in bone and joint
3294–3302. disease. Semin Arthritis Rheum 2000;30:87–99.
84. Lees P, Higgins AJ. Clinical pharmacology and therapeutic uses of 107. Munsterman AS, Bertone AL, Zachos TA, et al. Effects of the
non‐steroidal anti‐inflammatory drugs in the horse. Equine Vet J omega‐3 fatty acid, alpha‐linolenic acid, on lipopolysaccharide‐
1985;17:83–96. challenged synovial explants from horses. Am J Vet Res 2005;
85. Letendre LT, Tessman RK, McClure SR, et al. Pharmacokinetics of 66:1503–1508.
firocoxib after administration of multiple consecutive daily doses 108. Neil KM, Caron JP, Orth MW. The role of glucosamine and
to horses. Am J Vet Res 2008;69:1399–1405. chondroitin sulfate in treatment for and prevention of osteoar-
86. Liang Z, Leslie J, Adebowale A, et al. Determination of the nutra- thritis in animals. J Am Vet Med Assoc 2005;226:1079–1088.
ceutical, glucosamine hydrochloride, in raw materials, dosage 109. Noble G, Edwards S, Lievaart J, et al. Pharmacokinetics and
forms and plasma using pre‐column derivatization with ultravio- safety of single and multiple oral doses of meloxicam in adult
let HPLC. J Pharm Biomed Anal 1999;20:807–814. horses. J Vet Intern Med 2012;26:1192–1201.
87. Liang Z, Bonneville C, Senez T, et al. Development and validation 110. O’Connor CI, Lawrence LM, Hayes SH. Dietary fish oil supple-
of a photometric titration method for the quantitation of sodium mentation affects serum fatty acid concentrations in horses.
chondroitin sulfate (bovine) in Cosequin DS chewable tablet. J Anim Sci 2007;85:2183–2189.
J Pharm Biomed Anal 2002;28:245–249. 111. Oke S, Aghazadeh‐Habashi A, Weese JS, et al. Evaluation of glu-
88. Liau YH, Horowitz MI. Desulfation and depolymerization of chon- cosamine levels in commercial equine oral supplements for
droitin 4‐sulfate and its degradation products by rat stomach, liver joints. Equine Vet J 2006;38:93–95.
and small intestine. Proc Soc Exp Biol Med 1974;146:1037–1043. 112. Orsini JA, Ryan WG, Carithers DS, et al. Evaluation of oral
89. Liau YH, Galicki N, Horowitz MI. Degradation of chondroitin administration of firocoxib for the management of musculoskel-
4‐sulfate by rat stomach exoglycosidases, sulfohydrolase and hya- etal pain and lameness associated with osteoarthritis in horses.
luronidase‐like enzymes. Digestion 1981;21:117–124. Am J Vet Res 2012;73:664–671.
90. Lippiello L, Prudhomme A. Advantageous use of glucosamine 113. Orth MW, Peters TL, Hawkins JN. Inhibition of articular carti-
combined with S‐Adenosylmethionine in veterinary medicine: lage degradation by glucosamine‐HCl and chondroitin sulphate.
preservation of articular cartilage in joint disorders. Intern J Appl Equine Vet J Suppl 2002;34:224–229.
Res Vet Med 2005;3:6–12. 114. Parcell S. Sulfur in human nutrition and applications in medi-
91. Lippiello L, Woodward J, Karpman R, et al. In vivo chondro‐pro- cine. Altern Med Rev 2002;7:22–44.
tection and metabolic synergy of glucosamine and chondroitin 115. Platt D. Articular cartilage homeostasis and the role of growth
sulfate. Clin Orthop Relat Res 2000:229–240. factors and cytokines in regulating matrix composition. In Joint
92. Machlin LJ, Bendich A. Free radical tissue damage: protective role Disease in the Horse, 1st ed. McIlwraith CW, Trotter GW, eds.
of antioxidant nutrients. FASEB J 1987;1:441–445. WB Saunders, Philadelphia, 1996;29–39.
93. Maheu E, Mazieres B, Valat JP, et al. Symptomatic efficacy of avo- 116. Raidal SL, Edwards S, Pippia J, et al. Pharmacokinetics and
cado/soybean unsaponifiables in the treatment of osteoarthritis of safety of oral administration of meloxicam to foals. J Vet Intern
the knee and hip: a prospective, randomized, double‐blind, pla- Med 2013;27:300–307.
cebo‐controlled, multicenter clinical trial with a six‐month treat- 117. Raidal SL, Hughes KJ, Charman A‐L, et al. Effects of meloxicam
ment period and a two‐month follow‐up demonstrating a and phenylbutazone on renal responses to furosemide, dobu-
persistent effect. Arthritis Rheum 1998;41:81–91. tamine, and exercise in horses. Am J Vet Res 2014;75:668–679.